TSW
AMED

Thompson Siegel & Walmsley’s Amedisys AMED Stock Holding History

Thompson Siegel & Walmsley’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,500
Closed -$431K – 565
2022
Q1 		$431K Hold
2,500
– – 0.01% 322
2021
Q4 		$405K Buy
2,500
+1,000
+67% +$161K 0.01% 326
2021
Q3 		$224K Buy
+1,500
New +$312K ﹤0.01% 361

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Thompson Siegel & Walmsley's AMED Position: Q2 2022 in Review

Thompson Siegel & Walmsley sold out of Amedisys (AMED) in Q2 2022, closing a stake of 2,500 shares — an estimated $431K sold.

Thompson Siegel & Walmsley first reported a position in AMED in Q3 2021 and held it in 3 quarters. The position peaked at $431K in Q1 2022. 288 funds tracked by Wall St. Rank hold AMED as of Q2 2022.

  • Thompson Siegel & Walmsley reported no remaining Amedisys position as of Q2 2022 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 2,500 Amedisys shares in Q2 2022, an estimated $431K.
  • Thompson Siegel & Walmsley first reported a position in Amedisys in Q3 2021 and held it in 3 quarters.
  • Thompson Siegel & Walmsley's Amedisys position peaked at $431K in Q1 2022.
  • 288 funds tracked by Wall St. Rank held Amedisys as of Q2 2022.

Based on Thompson Siegel & Walmsley's 13F filing for Q2 2022, filed 22 Jul 2022.